Boston Scientific Corp. (BSX) continuously managed to outperform its competitors, despite periodic losses. Recently, the company has made strides in the financial growth reflected by
increasing stock holdings by Brookstone Capital Management and Courier Capital LLC. In terms of major milestones, Boston Scientific boldly decided to acquire Silk Road Medical for
US$1.16 Billion, aiming to expand its portfolio in the medical field. Furthermore, it announced the
completion of a €2.0 Billion offering of Senior Notes. As for the annual financials, the company showed
remarkable results, with full year and Q1 2024 earnings beating estimates, leading to a surge in the share price. They also hiked their profit forecast for 2024, citing robust growth from cardiovascular devices. Boston Scientific faced minor setbacks with their shares' performance on some trading days but bounced back strongly, maintaining solid momentum in the long term. New collaborative deals with Scivita Medical and productive acquisitions such as Axonics, Inc., Relievant Medsystems, Inc., and Silk Road Medical, Inc. were crucial in its value augmentation. The company also gained FDA approval for its AGENT™ Drug-Coated Balloon and FARAPULSE™ Pulsed Field Ablation System, bolstering its contributions to the healthcare sector.
Boston Scientific Corp BSX News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 30 Jun 2024 09:14:37 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
